Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026 BlogsHiRO Updates

Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026

HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…

harvestiroApril 20, 2026

Meet HiRO at COG New England Conference on April 28-29! BlogsHiRO Updates

Meet HiRO at COG New England Conference on April 28-29!

HiRO to Attend COG New England Conference, April 28–29 Clinical development is becoming increasingly global,…

harvestiroApril 20, 2026

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell and Gene Therapy BlogsHiRO Updates

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell and Gene Therapy

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell…

harvestiroApril 17, 2026

Connect with HiRO at the 2026 AAD Annual Meeting in Denver – Booth #209 HiRO Updates

Connect with HiRO at the 2026 AAD Annual Meeting in Denver – Booth #209

Heading to the 2026 AAD Annual Meeting? Connect with the HiRO Team in Denver The…

harvestiroMarch 30, 2026

Meet HiRO at PHUSE US Connect 2026 in Austin – Booth #26 HiRO Updates

Meet HiRO at PHUSE US Connect 2026 in Austin – Booth #26

We’re excited to join PHUSE US Connect 2026, taking place March 22–26, 2026 in Austin,…

harvestiroMarch 30, 2026

HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment HiRO Updates

HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment

SOMERSET, N.J., March 3, 2026 -- Harvest Integrated Research Organization (HiRO), a global contract research…

Vicky HuiMarch 3, 2026

Successful Rescue and Transition of a Phase I Oncology Study for a US Biotech Company Case Studies

Successful Rescue and Transition of a Phase I Oncology Study for a US Biotech Company

Overview A US biotech company's Phase I oncology study had stalled under the management of…

Vicky HuiJanuary 29, 2026

Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company Case Studies

Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company

This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…

Vicky HuiJanuary 29, 2026

Understanding the US FDA’s Special Designations and Approval Pathways Blogs

Understanding the US FDA’s Special Designations and Approval Pathways

Recognizing the challenges of drug development, the US FDA has established several special designations and…

Vicky HuiJanuary 26, 2026

US FDA Regulatory Meetings Blogs

US FDA Regulatory Meetings

Understanding the various types of regulatory meetings available with the US FDA is crucial for…

Vicky HuiJanuary 30, 2026

Leveraging China to Maximize Global Study Impact Blogs

Leveraging China to Maximize Global Study Impact

China's healthcare market is expanding rapidly due to urbanization, with a population of about 1.4…

Vicky HuiJanuary 26, 2026

Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty Blogs

Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty

Navigating the Next Few Years with Confidence   2025 has been marked by significant regulatory…

Vicky HuiJanuary 28, 2026